Eli Lilly – media

Genentech Lawsuit against Eli Lilly’s Antipsoriasis Drug TALZ

Genentech recently won the patent for a psoriasis drug. Unfortunately, Roche’s Genentech unit prosecuted Eli Lilly for violation by claiming their psoriasis drugTalz, infringes on one of their patents.
- Source: FiercePharma
- 970
- July 9, 2018
Company Insight Eli Lilly lawsuit psoriasis Roche
Lilly and China’s NCCD announce collaboration to advance scientific understanding and care for people living with diabetes and cardiovascular disease

Collaboration between China's National Center for Cardiovascular Diseases and Lilly aims to improve care for people living with Type 2 diabetes in China - The Lilly and NCCD collaboration will address four strategic areas to advance scientific understanding and medical education related to diabetes and cardiovascular disease
- Source: prnewswire
- 524
- April 26, 2018
Company Insights CVD Eli Lilly NCCD
FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate. While the Advisory Committee unanimously supported the efficacy of the 4-mg dose of baricitinib, it did not recommend approval of the 4-mg dose of baricitinib for the proposed indication based on the adequacy of the safety and benefit-risk profiles.
- Source: prnewswire
- 679
- April 25, 2018
baricitinib Eli Lilly New Approvals RA
FDA ‘conflicted’ on Lilly and Incyte’s refiled baricitinib

Eli Lilly and Incyte’s second attempt to get U.S. approval of rheumatoid arthritis drug baricitinib could be scuppered again by lingering FDA concerns about safety. A briefing document published ahead of the April 23 advisory committee meeting on baricitinib suggests that Lilly and Incyte’s lightning-fast amendment and refile of the dossier hasn’t added enough data to persuade the FDA to change its stance on the risk of blood clots with the JAK inhibitor.
- Source: Fiercebiotech; new approvals
- 618
- April 24, 2018
baricitinib Eli Lilly FDA rheumatoid arthritis

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.